Type 2 Diabetes Mellitus S4.2-1. Huo R, Du T, Xu Y, et al. Effects of Mediterranean-style diet on gly- cemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis. Eur J Clin Nutr. 2015;69:1200 8. S4.2-2. Azadbakht L, Fard NRP, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovas- cular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011;34:55 7. S4.2-3. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006;29:2518 27. S4.2-4. Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resis- tance training on hemoglobin A1c levels in patients with type 2 dia- betes: a randomized controlled trial. JAMA. 2010;304:2253 62. S4.2-5. Effect of intensive blood-glucose control with metformin on com- plications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854 65. S4.2-6. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740 51. S4.2-7. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304 11. S4.2-8. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascu- lar disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620 9. S4.2-9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovas- cular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117 28. S4.2-10. Neal B, Perkovic V, Mahaffey KW, et al. 